NCT00698061View on ClinicalTrials.gov

Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y

PHASE3CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

September 30, 2000

Study Completion Date

May 31, 2001

Conditions
Hepatitis B
Interventions
BIOLOGICAL

HBV-MPL vaccine 208129

3-dose primary vaccination and booster vaccination by intramuscular injection

BIOLOGICAL

Engerix™-B

3-dose primary vaccination and booster vaccination by intramuscular injection

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00698061 - Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y | Biotech Hunter | Biotech Hunter